Source comparison
Comparison: Melanotan-1 vs Melanotan-2 Tanning Timeline
MC1R Receptor Selectivity Highly selective for MC1R (melanocytes) Non-selective; also activates MC3R, MC4R, MC5R MT-1's selectivity reduces side effects but may slow initial tanning by 1–2 days vs MT-2's multi-receptor activation Visible Tanning Timeline 5–14
This comparison does not assign a generated winner or score.
- MC1R Receptor Selectivity
- Highly selective for MC1R (melanocytes)
- Non-selective; also activates MC3R, MC4R, MC5R
- MT-1's selectivity reduces side effects but may slow initial tanning by 1–2 days vs MT-2's multi-receptor activation
- Visible Tanning Timeline
- 5–14 days
- 3–10 days
- MT-2's broader receptor activation accelerates early melanogenesis, but the difference narrows by week 3
- Side Effect Profile
- Nausea (10–15% of users), flushing (mild)
- Nausea (40–50%), spontaneous erections (males), darkening of existing moles
- MT-1's MC1R selectivity avoids most MC4R-mediated effects; better tolerability for users prioritizing safety over speed
- Regulatory Status
- FDA-approved for erythropoietic protoporphyria (brand name Scenesse)
- Not FDA-approved; research peptide only
- MT-1 has established clinical safety data; MT-2 lacks formal approval and carries higher legal/medical risk
- Maintenance Dosing Frequency
- 2–3 times weekly at 0.25–0.5 mg
- 1–2 times weekly at 0.25–0.5 mg
- Both maintain plateau tan effectively; MT-2's longer half-life allows slightly less frequent dosing
- Tan Fade Rate Post-Discontinuation
- 4–6 weeks to baseline
- 3–5 weeks to baseline
- Minimal difference; fade rate primarily determined by keratinocyte turnover, not peptide pharmacokinetics
- Melanotan-2 activates MC3R and MC4R receptors alongside MC1R, which increases appetite suppression and libido effects but also accelerates early melanin synthesis through additional signaling pathways. This shortens the timeline to visible tanning by 2–4 days compared to Melanotan-1. However, MT-2's non-selectivity produces substantially higher side effect rates. Our experience with researchers in this space consistently shows that 40–50% of MT-2 users report nausea severe enough to reduce dosing or stop entirely, compared to 10–15% with MT-1.
- For users prioritizing safety and tolerability, Melanotan-1's slightly longer timeline is a worthwhile trade-off. The final tan depth at 4–6 weeks is comparable between the two peptides when dosing protocols are optimized. MT-2's early advantage disappears by week three.